Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMMPNASDAQ:MGXNASDAQ:SLRNNASDAQ:YMAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMMPImmutep$1.51+1.3%$1.79$1.32▼$3.34$219.79M1.94193,834 shs33,078 shsMGXMetagenomi$1.57+3.3%$1.90$1.23▼$8.86$58.69M-0.27762,231 shs481,350 shsSLRNAcelyrin$2.23+2.3%$2.43$1.85▼$7.25$225.02M1.121.22 million shs603,326 shsYMABY-mAbs Therapeutics$5.35+8.5%$5.14$3.86▼$17.78$241.92M0.71333,170 shs273,605 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMMPImmutep+2.05%+4.93%-16.29%-22.80%-40.16%MGXMetagenomi+2.70%+6.29%-21.65%-44.93%-83.04%SLRNAcelyrin-2.24%-5.63%-20.73%+3.81%-59.40%YMABY-mAbs Therapeutics+2.07%+15.19%+5.57%-22.12%-65.69%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMMPImmutep1.6291 of 5 stars3.52.00.00.03.30.00.0MGXMetagenomi1.8586 of 5 stars3.42.00.00.02.80.00.0SLRNAcelyrin3.5702 of 5 stars3.25.00.00.03.13.31.3YMABY-mAbs Therapeutics3.7078 of 5 stars4.53.00.00.02.34.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMMPImmutep 3.00Buy$8.50462.91% UpsideMGXMetagenomi 2.80Moderate Buy$13.00728.03% UpsideSLRNAcelyrin 2.40Hold$9.60330.49% UpsideYMABY-mAbs Therapeutics 2.91Moderate Buy$18.30242.06% UpsideCurrent Analyst Ratings BreakdownLatest MGX, YMAB, SLRN, and IMMP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/3/2025MGXMetagenomiHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $7.003/21/2025YMABY-mAbs TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $12.003/18/2025MGXMetagenomiWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$25.00 ➝ $20.003/5/2025YMABY-mAbs TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $18.003/5/2025YMABY-mAbs TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$14.00 ➝ $12.003/5/2025YMABY-mAbs TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$11.00 ➝ $7.003/3/2025YMABY-mAbs TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$23.00(Data available from 4/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMMPImmutep$5.14M42.76N/AN/A$1.05 per share1.44MGXMetagenomi$52.30M1.12N/AN/AN/A∞SLRNAcelyrinN/AN/AN/AN/A$6.74 per shareN/AYMABY-mAbs Therapeutics$87.69M2.76N/AN/A$2.32 per share2.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMMPImmutep-$28.01MN/A0.00N/AN/AN/AN/AN/AN/AMGXMetagenomi-$68.25M-$2.62N/AN/AN/A-134.27%-43.23%-18.86%5/13/2025 (Estimated)SLRNAcelyrin-$381.64M-$2.50N/AN/AN/AN/A-44.12%-39.02%5/13/2025 (Estimated)YMABY-mAbs Therapeutics-$21.43M-$0.67N/AN/AN/A-28.22%-24.61%-18.49%5/6/2025 (Estimated)Latest MGX, YMAB, SLRN, and IMMP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025MGXMetagenomi-$0.62N/AN/AN/AN/AN/A5/13/2025Q1 2025SLRNAcelyrin-$0.95N/AN/AN/AN/AN/A5/6/2025Q1 2025YMABY-mAbs Therapeutics-$0.21N/AN/AN/A$19.97 millionN/A3/19/2025Q4 2024SLRNAcelyrin-$0.86-$0.79+$0.07-$0.79N/AN/A3/17/2025Q4 2024MGXMetagenomi-$0.62-$0.63-$0.01-$0.63$13.18 million$9.61 million3/4/2025Q4 2024YMABY-mAbs Therapeutics-$0.13-$0.15-$0.02-$0.15$26.70 million$26.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMMPImmutepN/AN/AN/AN/AN/AMGXMetagenomiN/AN/AN/AN/AN/ASLRNAcelyrinN/AN/AN/AN/AN/AYMABY-mAbs TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMMPImmutep0.0118.2518.25MGXMetagenomiN/A6.186.18SLRNAcelyrinN/A7.157.15YMABY-mAbs TherapeuticsN/A3.923.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMMPImmutep2.32%MGXMetagenomiN/ASLRNAcelyrin87.31%YMABY-mAbs Therapeutics70.85%Insider OwnershipCompanyInsider OwnershipIMMPImmutep3.07%MGXMetagenomiN/ASLRNAcelyrin13.60%YMABY-mAbs Therapeutics22.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMMPImmutep2,021145.56 million141.09 millionOptionableMGXMetagenomi23637.38 millionN/AN/ASLRNAcelyrin135100.91 million86.68 millionOptionableYMABY-mAbs Therapeutics15045.22 million34.71 millionOptionableMGX, YMAB, SLRN, and IMMP HeadlinesRecent News About These CompaniesY-mAbs Therapeutics: A Yawn From The Market Means OpportunityApril 11, 2025 | seekingalpha.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Bought by Pictet Asset Management Holding SAApril 5, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Rating of "Moderate Buy" by BrokeragesMarch 26, 2025 | marketbeat.comBreaking Down Y-mAbs Therapeutics: 5 Analysts Share Their ViewsMarch 23, 2025 | nasdaq.comHC Wainwright Cuts Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $12.00March 22, 2025 | marketbeat.comY-mAbs Therapeutics price target lowered to $12 from $22 at H.C. WainwrightMarch 21, 2025 | markets.businessinsider.com4YMAB : Breaking Down Y-mAbs Therapeutics: 5 Analysts Share Their ViewsMarch 21, 2025 | benzinga.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) CEO Michael J. Rossi Sells 3,917 SharesMarch 12, 2025 | insidertrades.comBearish: Analysts Just Cut Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Revenue and EPS estimatesMarch 9, 2025 | finance.yahoo.comForecasting The Future: 4 Analyst Projections For Y-mAbs TherapeuticsMarch 5, 2025 | benzinga.comY-mAbs Therapeutics price target lowered to $12 from $14 at BofAMarch 5, 2025 | markets.businessinsider.comY-Mabs Therapeutics (YMAB) Gets a Buy from OppenheimerMarch 5, 2025 | markets.businessinsider.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2024 Earnings Call TranscriptMarch 5, 2025 | msn.comY-mAbs Therapeutics, Inc. (YMAB) Q4 2024 Earnings Call TranscriptMarch 4, 2025 | seekingalpha.comY-mAbs Therapeutics, Inc.: Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate DevelopmentsMarch 4, 2025 | finanznachrichten.deY-mAbs Shares Fall After Outlook, 4Q Revenue MissMarch 4, 2025 | marketwatch.comY-mAbs Therapeutics reports Q4 EPS (15c), consensus (13c)March 4, 2025 | markets.businessinsider.comY-mAbs Therapeutics sees 2025 revenue $75M-$90M, consensus $105.76MMarch 4, 2025 | markets.businessinsider.comY-mAbs Therapeutics (NASDAQ:YMAB) shareholders have endured a 79% loss from investing in the stock five years agoMarch 4, 2025 | finance.yahoo.comY-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Lags Revenue EstimatesMarch 4, 2025 | zacks.comY-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate DevelopmentsMarch 4, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMGX, YMAB, SLRN, and IMMP Company DescriptionsImmutep NASDAQ:IMMP$1.51 +0.02 (+1.34%) Closing price 04:00 PM EasternExtended Trading$1.50 -0.01 (-0.66%) As of 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.Metagenomi NASDAQ:MGX$1.57 +0.05 (+3.29%) Closing price 04:00 PM EasternExtended Trading$1.52 -0.06 (-3.50%) As of 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.Acelyrin NASDAQ:SLRN$2.23 +0.05 (+2.29%) Closing price 04:00 PM EasternExtended Trading$2.22 0.00 (-0.22%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.Y-mAbs Therapeutics NASDAQ:YMAB$5.35 +0.42 (+8.52%) Closing price 04:00 PM EasternExtended Trading$5.36 +0.01 (+0.09%) As of 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Stock is a Buy as Cyberthreat Environment Expands Congress! Who Traded What During the Tariff-Induced Meltdown Beware of BigBear.ai: Insiders Are Selling—Should You? NATO Deal Sparks 4% Jump in Palantir Stock—What’s Next? Microsoft: A Blend of Growth and Value Amid Tariff Concerns Why NVIDIA Stock Could Soar Despite Wall Street Downgrades Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold Don’t Fear, New Highs for Fastenal Will Soon Be Here Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
